Artiva Biotherapeutics, Inc. (ARTV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Artiva Biotherapeutics, Inc. (ARTV) Healthcare & Pipeline Overview

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancers. Their lead candidate, AB-101, represents a novel off-the-shelf approach, positioning Artiva to potentially disrupt the cell therapy landscape.

What Is the Investment Thesis for ARTV?

Artiva Biotherapeutics presents a notable research candidate within the allogeneic NK cell therapy space. The company's lead product candidate, AB-101, targets a broad range of autoimmune diseases and cancers, addressing significant unmet medical needs. A key value driver is the off-the-shelf nature of AB-101, which offers logistical and scalability advantages over autologous cell therapies. Upcoming clinical trial results for AB-101 in lupus nephritis and other indications could serve as major catalysts. The company's pipeline of CAR-NK cell therapies, including AB-201 and AB-205, provides further upside potential. Potential risks include clinical trial failures, regulatory hurdles, and competition from other cell therapy companies. With a market cap of $545M and a beta of 2.19, Artiva offers high-risk, high-reward exposure to the rapidly evolving cell therapy market.

Based on FMP financials and quantitative analysis

ARTV Key Highlights

Artiva is a clinical-stage biotechnology company focused on NK cell therapies.

• Lead product candidate AB-101 targets autoimmune diseases and cancers.
• Off-the-shelf NK cell therapy approach offers logistical advantages.
• Developing CAR-NK cell therapies AB-201 and AB-205 for enhanced cancer targeting.
• Headquartered in San Diego, California, with 96 employees.

Who Are ARTV's Competitors?

ARTV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ARTV's Key Strengths?

Novel off-the-shelf NK cell therapy platform.

• Pipeline of CAR-NK cell therapies.
• Experienced management team.
• Strong intellectual property position.

What Are ARTV's Weaknesses?

Clinical-stage company with no approved products.

• High cash burn rate.
• Dependence on clinical trial success.
• Limited manufacturing capacity.

What Could Drive ARTV Stock Higher?

Clinical trial results for AB-101 in lupus nephritis.

• Clinical trial results for AB-101 in rheumatoid arthritis.
• Initiation of clinical trials for AB-201.
• Enrollment of patients in ongoing clinical trials.

What Are the Key Risks for ARTV?

Negative return on equity (-73.2%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for AB-101 or other product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from other cell therapy companies.
• Patent challenges or infringement claims.
• High cash burn rate and need for additional financing.

What Are the Growth Opportunities for ARTV?

• Expansion of AB-101 into additional autoimmune indications: Artiva has the opportunity to expand the clinical development of AB-101 into additional autoimmune diseases beyond the current targets of lupus nephritis, rheumatoid arthritis, and pemphigus vulgaris. The market for autoimmune disease therapies is substantial, with a global market size estimated at $130 billion. Positive clinical data in these additional indications could significantly increase the market potential for AB-101.
• Advancement of CAR-NK cell therapies AB-201 and AB-205: Artiva's CAR-NK cell therapies, AB-201 and AB-205, represent a significant growth opportunity in the oncology space. AB-201 targets HER2-expressing tumors, while AB-205 targets CD5-expressing tumors. The CAR-NK cell therapy market is projected to experience rapid growth, driven by the potential for enhanced efficacy and safety compared to traditional CAR-T cell therapies. Successful clinical development of AB-201 and AB-205 could position Artiva as a leader in the CAR-NK cell therapy field.
• Strategic partnerships and collaborations: Artiva can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its NK cell therapies. These partnerships could provide access to additional funding, expertise, and resources, enabling Artiva to expand its pipeline and reach a broader patient population. The biotechnology industry is characterized by frequent collaborations, and Artiva is well-positioned to leverage this trend.
• Expansion of manufacturing capabilities: As Artiva's pipeline advances, the company will need to expand its manufacturing capabilities to meet the anticipated demand for its NK cell therapies. Investing in state-of-the-art manufacturing facilities will be crucial for ensuring a reliable supply of product and maintaining a competitive advantage. The cell therapy manufacturing market is experiencing significant growth, and Artiva needs to be prepared to capitalize on this trend.
• Geographic expansion into new markets: Artiva has the opportunity to expand its geographic reach beyond the United States and into international markets. The global market for cell therapies is growing rapidly, and Artiva can tap into this growth by establishing a presence in key regions such as Europe and Asia. This expansion would require navigating regulatory hurdles and establishing partnerships with local distributors, but the potential rewards are substantial.

What Are ARTV's Competitive Advantages?

• Proprietary NK cell therapy platform.
• Off-the-shelf approach offers scalability advantages.
• Strong intellectual property portfolio.
• Experienced management team with expertise in cell therapy development.

What Does ARTV Do?

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company founded in 2019 and headquartered in San Diego, California. The company is dedicated to developing novel allogeneic natural killer (NK) cell therapies for the treatment of autoimmune diseases and cancers. Artiva's primary focus is on creating off-the-shelf NK cell therapies that can be readily administered to patients, overcoming the limitations associated with autologous cell therapies, which require patient-specific manufacturing. Their lead product candidate, AB-101, is an off-the-shelf NK cell therapy being developed for a range of autoimmune diseases and cancers, including lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell non-Hodgkin lymphoma. In addition to AB-101, Artiva is also developing AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate, and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. These CAR-NK cell therapies are designed to enhance the targeting and killing of cancer cells. Artiva's approach leverages the natural ability of NK cells to recognize and eliminate diseased cells, offering a potentially safer and more effective treatment option for patients with cancer and autoimmune disorders.

What Products and Services Does ARTV Offer?

• Develop off-the-shelf natural killer (NK) cell therapies.
• Target autoimmune diseases and cancers.
• Lead product candidate is AB-101.
• Developing allogeneic anti-HER2 CAR-NK cell product candidate AB-201.
• Developing allogeneic anti-CD5 CAR-NK cell product candidate AB-205.
• Conduct clinical trials to evaluate the safety and efficacy of their therapies.
• Focus on creating scalable and cost-effective cell therapy solutions.

How Does ARTV Make Money?

• Develop and out-license NK cell therapy products.
• Generate revenue through licensing agreements and milestone payments.
• Potentially generate revenue through direct sales of approved therapies.

What Industry Does ARTV Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in cell and gene therapies. Artiva Biotherapeutics is positioned within this evolving landscape, focusing on allogeneic NK cell therapies. The competitive landscape includes companies developing both autologous and allogeneic cell therapies, such as CRISPR Therapeutics and Nkarta Therapeutics. Artiva's off-the-shelf approach offers a potential advantage in terms of scalability and cost-effectiveness.

Who Are ARTV's Key Customers?

• Patients suffering from autoimmune diseases.
• Patients suffering from various cancers.
• Hospitals and oncology centers.

Wall Street analysts project Artiva Biotherapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-2.59.

ARTV Valuation & Market Position

With a $545M market cap, Artiva Biotherapeutics, Inc. sits in the small-cap segment of the market. Relative to its peer group, ARTV's quantitative score of 50/100 is below the peer average of 77/100.

Return on equity for Artiva Biotherapeutics, Inc. stands at -73.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -82.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -43.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.16 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -47.5%, the inverse of the P/E and a quick read on earnings relative to price.

Artiva Biotherapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 15.09 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Artiva Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Fred Aslan. ARTV has traded publicly since 2024.

ARTV Financials

ARTV Latest News

No recent news available for ARTV.

ARTV Analyst Consensus

ARTV MoonshotScore

Artiva Biotherapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources